B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Director CMC Product Development - Small Molecule

Bioprocess & BiomanufacturingUpdated on Nov 10
Full-timeDurham, NC, USA$199k - $258k

About the Job

Requirements

  • At least 10 years of pharmaceutical drug product development and manufacturing experience focused on small molecules in the pharmaceutical or biotechnology industry.
  • A demonstrated track record serving as the primary scientific lead on formulation and drug product process development programs from early to late clinical phases.
  • Deep technical expertise in solid oral dosage form development, including immediate-release, modified-release, and amorphous solid dispersions; formulation selection; manufacturing process development; scale-up; technical transfer; commercial process optimization; and validation.
  • Proven experience selecting and managing external partner relationships, including contract development and manufacturing organizations (CDMOs) and contract laboratories, with technical oversight, work order management, change control, deviation resolution, and performance monitoring.
  • Comprehensive knowledge of ICH Q8/Q9/Q10/Q11, current good manufacturing practice (cGMP) requirements, and FDA/EMA drug product development expectations.
  • Experience authoring drug product sections of INDs, IMPDs, and NDA filings and contributing to FDA or EMA responses on formulation, manufacturing, and drug product control strategy topics.
  • A proven track record operating effectively in a pre-commercial, resource-constrained environment, balancing strategic vision with hands-on execution and infrastructure building.
  • Experience managing cross-functional stakeholder relationships at the senior level, influencing without authority, and aligning diverse teams around shared program goals.
  • Strong written and verbal communication skills, including authoring high-quality regulatory documents, scientific reports, and executive-level presentations.
  • A track record of building productive working relationships across CMC functions, Clinical Development, Clinical Pharmacology, Regulatory Affairs, and Quality.
  • Ability to manage competing priorities, proactively flag risks, and keep cross-functional stakeholders aligned on timelines and deliverable status.
  • Ability to travel 20% or more as needed, including occasional overnight stays.

Responsibilities

  • Define and execute drug product development strategy for assigned small molecule programs, including formulation approach, manufacturing platform, and the development roadmap supporting clinical and regulatory plans.
  • Lead formulation development for small molecule drug candidates across clinical phases, including excipient screening, compatibility studies, formulation optimization, and selection of final drug product composition for clinical and commercial manufacturing.
  • Direct and oversee drug product process development, technical transfer, scale-up, process optimization, registration batch execution, and process validation/PPQ for solid oral dosage forms and other small molecule drug delivery systems.
  • Serve as the primary technical interface with CDMO drug product teams for assigned programs by defining activity scope, providing scientific oversight of formulation and manufacturing campaigns, reviewing documents, resolving deviations, and holding partners accountable to quality and timeline commitments.
  • Author and review drug product sections of regulatory submissions, including IND, IMPD, NDA, and MAA, covering formulation descriptions, manufacturing process narratives, container-closure justifications, control strategies, and process validation approaches.
  • Lead technical responses to FDA and EMA questions on drug product topics and support health authority meetings.
  • Integrate Quality by Design (QbD) principles and Design of Experiments (DoE) into formulation and process development decisions, establishing critical quality attributes (CQAs), critical process parameters (CPPs), and design spaces.
  • Collaborate with Analytical Development to define drug product release and stability specifications, in-process controls, and comparability strategies for formulation and process changes.
  • Lead packaging development and container-closure system selection for clinical and commercial drug product presentations, including compatibility assessment and child-resistant packaging requirements.
  • Contribute manufacturing timelines, batch size projections, and drug product release schedules to Clinical Supply Chain to support trial startup, enrollment milestones, and uninterrupted clinical supply.
  • Evaluate drug delivery technology options and novel dosage form strategies for pipeline candidates, providing formulation feasibility assessments and manufacturability input during candidate selection and early development planning.
  • Contribute to CMC due diligence assessments and portfolio planning by evaluating the manufacturability and development feasibility of small molecule drug product candidates.
  • Perform other duties and responsibilities as assigned.

Desired Qualifications

  • A Ph.D. in Pharmaceutical Sciences, Pharmaceutics, Chemical Engineering, or a closely related discipline, or equivalent industry experience.

About the Company

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Beeline Medicines focuses on precision therapies for autoimmune and inflammatory diseases, advancing a portfolio of in-licensed programs from Bristol Myers Squibb with strong backing from Bain Capital. Its lead, afimetoran, is an oral TLR7/8 inhibitor for lupus, with lomedeucitinib as an allosteric TYK2 inhibitor and two IND-stage biologics targeting IL-18 and IL-10 pathways to modulate immune signaling. The company differentiates itself by combining externally sourced programs with a leadership team experienced in drug development and commercialization, pursuing multiple mechanism-driven candidates rather than a single modality, supported by substantial early funding. Its goal is to move its clinical-stage therapies toward pivotal trials and bring targeted immune-modulating treatments to patients, beginning with completing Phase 2 for afimetoran in late 2026 and following with a pivotal program.

Company size
51-200
Company stage
Series A
Total funding
$426.3M
Headquarters
Stamford, CT
Founded
2025

Recently Posted Jobs

Explore more opportunities at Beeline Medicines

See more jobs